BluGlass Limited Overview
BluGlass is a micro-cap, vertically integrated gallium nitride (GaN) visible laser diode developer and manufacturer with epitaxy operations in Sydney and a laser fabrication facility in Fremont, California. It describes itself as one of only a handful of end-to-end GaN laser manufacturers globally and one of just two GaN laser suppliers with US manufacturing, a position it is leveraging into US defence, aerospace, quantum, biotech and AI-infrastructure programs that increasingly require onshore supply. Its commercial model is "project-to-product": paid custom-development contracts (US Department of War CLAWS Hub, a US Tier-1 defence prime, a Fortune 500 data-storage company, Uviquity, TOPTICA, Coherent) intended to convert into recurring product supply. Revenue from customers remains small (A$4.1M in FY2026) and the company is loss-making (A$10.4M net loss), funded by equity raises and Australia's R&D Tax Incentive. A refreshed, US-oriented board led by Executive Chair Omer Granit recapitalised the company with A$14.6M in FY2026.
Company's own description (FY2026 Annual Report, paraphrased)
The FY2026 Directors' Report states that the Group's principal activity is the development and commercialisation of its visible GaN laser portfolio. This includes fulfilling product orders and foundry-service contracts, delivering technical milestones under customer-funded development programs, and advancing laser performance and manufacturing capability using both industry-standard MOCVD (metal-organic chemical vapour deposition) and BluGlass' proprietary low-temperature Remote Plasma Chemical Vapour Deposition (RPCVD) technology. The Group has operations in Australia and the USA, including a purpose-built production facility in Silicon Valley. ASX boilerplate describes BluGlass as a leading supplier of GaN laser diode products to the global photonics industry, focused on industrial, defence, bio-medical and scientific markets.
The Executive Chair's FY2026 letter frames the ambition as transforming BluGlass into a key onshore provider of critical photonic components to defence and aerospace, quantum, sensing and AI infrastructure, and signals intent to expand in the US and integrate complementary upstream technologies to move from component supplier toward systems provider.
Business model and revenue model
| Revenue channel | Nature | Recognition | FY2026 (AUD) | Strategic status |
|---|---|---|---|---|
| Laser Diode Project Revenue | Customer-funded custom development (NRE), government subcontracts (e.g., NCSU CLAWS Hub) | Over time, pro rata | 2,552,791 | Core — the "project" leg of project-to-product |
| Laser Diode Product Revenue | Sales of laser diodes, gain chips, DFB lasers, bars, packaged devices | Point in time | 498,212 | Core growth target |
| Foundry Services Revenue | Epitaxy/wafer and process services for third parties (legacy) | Point in time | 1,009,652 | Being exited ("deliberate transition away") |
| R&D Tax Incentive (other income) | Australian refundable R&D tax offset on eligible AU and US activities | Accrued when eligibility established | 6,116,957 | Non-customer funding; largest single income line |
BluGlass earns revenue through four channels (FY2026 Annual Report, Note 2):
Mix characterisation: In FY2026, customer revenue was 63% project (development services), 25% foundry services and 12% product. There is no subscription revenue. Licensing/IP revenue has been episodic — notably a A$1.93M (US$1.28M) IP-rights transfer payment from a European wafer developer received in July 2024 (booked in FY2024 per the Q4 FY2024 4C). The company is therefore, today, predominantly a contract R&D and development-services business with an embryonic component-sales line, financially underpinned by R&D tax refunds.
Value chain position
BluGlass is vertically integrated across the GaN laser value chain:
-
Epitaxy (wafer growth) — MOCVD and proprietary RPCVD, Silverwater, Australia.
-
Device design — single-mode, multi-mode, DFB, gain chips, tunable and MOPA architectures.
-
Wafer fabrication / front-end and back-end processing — Fremont, California fab (acquired 2022); contract-manufacturing capability brought in-house via the GaNWorks Foundry acquisition (completed early 2024).
-
Testing and packaging — packaged form factors (e.g., TO-can, butterfly, bars; specific catalogue details below), including integrated laser + optical amplifier packages for the Tier-1 defence prime program.
Management states that around 85% of manufacturing steps are shared across product lines (FY2026 CEO letter), supporting platform scalability.
Customer types and end-markets
| Customer type | Named examples (from filings/announcements) |
|---|---|
| Government / defence agencies | US Department of War (via NCSU-led CLAWS Hub, Microelectronics Commons); India Ministry of Defence (Solid State Physics Laboratory) |
| Defence primes | Unnamed US Tier-1 aerospace and defence prime (avionics, navigation systems) |
| Large corporates | Unnamed Fortune 500 mass-capacity data-storage leader; Coherent (collaboration) |
| Photonics/quantum companies | TOPTICA Photonics Inc. (US division), Infleqtion, Uviquity |
| Research institutions | University of Central Florida CREOL (repeat orders), Macquarie University (LiDAR project with Aurizn), North Carolina State University |
| AI infrastructure | Unnamed stealth-mode optical interconnect developer (feasibility study); unnamed AI infrastructure customer (purchase order) |
End-markets per management: defence and aerospace, quantum (computing and sensing), biotech/biomedical, scientific instrumentation, consumer electronics (AR), AI/data-centre optical interconnect, and data storage. Management states the US Government represents more than 60% of opportunities in its project pipeline, and investor materials (April 2026 placement presentation) state more than 80% of the pipeline is US-based.
Independent characterisation
BluGlass is best understood as a technically credible but sub-scale "option on visible GaN photonics" whose strategic value lies in (a) a rare US-located GaN laser fab, (b) a demonstrated ability to deliver bespoke high-fidelity visible lasers (DFB, single-mode, high-brightness MOPA), and (c) a growing roster of blue-chip development partners. The commercial model has not yet produced meaningful recurring product revenue — product sales were under A$0.5M in FY2026 — and the business consumed A$8.3M of operating cash flow in FY2026. The proprietary RPCVD technology, the company's founding thesis, is now a secondary differentiator; the FY2026 report says the company will continue to evaluate opportunities to leverage RPCVD where it supports shareholder value. The refreshed board's language about "inorganic opportunities" and moving "from component supplier to systems provider" suggests M&A may become a central lever.
Strategy
Stated strategy themes (FY2026 Annual Report, paraphrased)
-
"Project-to-product." Paid custom-development programs get BluGlass lasers "designed in" to next-generation customer systems, intended to convert into multi-year product supply agreements. Management acknowledges the transition can be lengthy and "will often include inorganic growth."
-
Leading US onshore visible laser company. Leverage the Fremont fab and approved CLAWS Hub supplier status to win US Government and defence-prime programs subject to sovereign supply-chain requirements.
-
US Government engagement and non-dilutive funding. Michael Best Strategies engagement; advisory relationship with Major General John F. Wharton (US Army, ret.); targeting Department of War and Department of Energy decision-makers.
-
Platform technology roadmap. Higher-power single-mode (MOPA), DFB, tunable lasers, longer wavelengths (aquamarine/green via UCSB SSLEEC licence), surface emitters for AI interconnects.
-
From component supplier to systems provider. Integrate complementary upstream technologies; explore broader opportunities, including leveraging US manufacturing capabilities (board statements, Dec 2025 and Aug 2026).
-
Recapitalisation and investor-base broadening. Completed A$14.6M FY2026 raise; US investor engagement; Board alignment through personal investment.
-
Focus on core. Exit legacy foundry; divest majority of Semiconductor Australia conference vehicle.
Strategic initiatives — last 24 months
| Date | Initiative | Type | Detail |
|---|---|---|---|
| Oct 2024 | Uviquity JDA | Partnership / development | Three-phase JDA with Master Supply Agreement option |
| FY2025 | CLAWS Year 2 | Government program | A$2.9M |
| 2,025 | India MoD supplier approval | Market entry | US$230k first order |
| Sep–Dec 2025 | Board refresh | Governance transformation | US-centred, investor-led board |
| Dec 2025 | 20:1 share consolidation | Capital markets | Re-based share price from ~A$0.01 to ~A$0.20+ |
| Jan 2026 | CLAWS Year 3 | Government program | A$1.05M |
| FY2026 | UCSB SSLEEC licence (further agreement) | IP / technology | AlGaN-layer long-wavelength visible laser IP |
| Mar 2026 | Tier-1 defence prime program | Commercial | A$1.25M |
| Mar 2026 | Michael Best Strategies | Government relations | DoW/DoE access |
| Apr 2026 | Fortune 500 collaboration | Commercial | A$1.3M |
| Apr–Jun 2026 | A$14.6M recapitalisation | Funding | Placement, options, shortfall |
| Jul 2026 | US$1.5M Uviquity promissory note | Strategic investment | 6% interest, 12-month maturity |
| Jul 2026 | Semiconductor Australia divestment | Portfolio simplification | Retain 19.9% with branding rights and profit share |
| Sep 2026 | Coherent collaboration | Partnership | A$286k co-development |
ESG/sustainability commitments and cost programs
No formal sustainability targets or cost-reduction programs with quantified targets are disclosed. The FY2026 report notes a deliberate reallocation of resources from foundry services to customer programs. The going-concern note retains the option to scale back development activities if required.
Medium-term targets and guidance
No formal financial guidance is provided. Management's stated focus is converting the US$100M project pipeline (29 opportunities as of March–April 2026) into contracts. Historical aspirational targets have not been met: in 2021–22 management aimed to capture 6–10% of the global laser diode market by 2026 (Edison research cited a market estimate of A$849M and potential revenue of almost A$75M), and the 2022 fab acquisition was said to have the potential to bring forward positive cash flows to 2024/2025. FY2026 customer revenue was A$4.1M and the company remains cash-flow negative. This track record should temper reliance on pipeline figures.
Products & Services
Pricing is not publicly disclosed for any product. Launch dates are given where disclosed.
Laser Diode Products
| Product / platform | Description and key capabilities | Target customers | Launch / latest milestone |
|---|---|---|---|
| Single-mode visible GaN lasers | High beam-quality (single-spatial-mode) blue/violet/near-UV lasers for precision applications | Quantum, sensing, biomedical, aerospace | World-record 1.25W single-mode (2025); 1.9W peak single-mode via MOPA (Q4 FY2026) |
| Multi-mode GaN laser diodes | Higher-power broad-area emitters across visible wavelengths | Industrial, scientific, defence | Product suite launched Jan 2023 (Photonics West) |
| GaN laser diode bars | Semi-custom multi-emitter bars | Research (e.g., UCF CREOL repeat orders, A$120k repeat order) | Ongoing |
| GaN Distributed Feedback (DFB) lasers | Single-frequency, narrow-linewidth visible lasers; IP partly licensed from UCSB SSLEEC | Quantum (atomic clocks, sensing), defence | First alpha DFB order c.2024; packaged DFB + amplifier for Tier-1 prime (2026) |
| GaN gain chips | Semiconductor optical gain elements for external-cavity and MOPA systems | Quantum (Infleqtion initial order), defence prime | Infleqtion PO FY2026; Tier-1 prime prototype testing passed |
| MOPA (master oscillator power amplifier) architecture | 450 nm single-mode oscillator + tapered amplifier; combines single-mode precision with high power | Aerospace, defence, quantum, biomedical | 1.9W demonstration FY2026 |
| High-peak-power CW tunable lasers | Novel tunable GaN designs; PCT application filed FY2026 | Aerospace/marine/defence, quantum, biotech | Development/IP stage |
| Custom PIC-ready lasers | High-precision single-frequency lasers for photonic integrated circuits | TOPTICA (NORDTECH Hub QUPICS program), Uviquity | TOPTICA order A$190k FY2026 |
| Long-wavelength visible (aquamarine/green) lasers | Extension of wavelength range using licensed UCSB SSLEEC AlGaN-layer IP | Quantum sensing, biomedical, AR, defence | Demonstrated range extension FY2026; licence FY2026 |
| GaN surface emitters | Early-stage feasibility for optical interconnect | AI computing / data-centre infrastructure (stealth customer) | Feasibility study FY2026 |
Development services (Laser Diode Projects)
| Program | Counterparty | Value | Scope | Status |
|---|---|---|---|---|
| CLAWS Hub Years 1–3 | NCSU / US Department of War Microelectronics Commons (CHIPS and Science Act funded) | A$6.5M (US$4.4M) cumulative | High-fidelity visible GaN lasers and integrated photonics | Year 3 underway (USFY2026); five-year program |
| Tier-1 defence prime program | Unnamed US aerospace/defence prime | A$1.25M (first A$560k PO) | Packaged DFB lasers + gain chips (laser + optical amplifier) for dual-use aerospace | 14–20/24-month program from Mar 2026 |
| Fortune 500 collaboration | Unnamed mass-capacity data-storage leader | A$1.3M (four milestone instalments) | Photonics R&D support | 12–18 months from Apr 2026 |
| Uviquity JDA | Uviquity (US start-up; AlN PIC/deep-UV) | Phase I A$1.2M (2024); Phase II A$1.4M (2026) | Heterogeneously integrated PICs; wafer/chip processing; packaging; laser supply | Phase II from Q3 CY2026; Master Supply Agreement contemplated |
| Coherent collaboration | Coherent | A$286k (US$200k) | Co-development of novel GaN device for scientific/medical markets | Announced 21 Sep 2026 |
| India MoD SSPL | Indian Ministry of Defence | US$230k | Benchmarking GaN laser diode fabrication process | Ongoing (referenced Apr 2026) |
| Ocean LiDAR | Macquarie University, Aurizn | — | Laser for subsurface water temperature and depth measurement | Status n/d |
| Applied Energetics | Applied Energetics | n/d (MOU) | Advanced defence/dual-use laser systems | Status n/d |
Foundry services (legacy, being exited)
Epitaxial growth and wafer services for third parties (including a European wafer developer to which IP was transferred in 2024). FY2026 revenue A$1.01M, down 40%; management stated the company reduced and ultimately exited these services.
RPCVD technology
Proprietary low-temperature, low-hydrogen, ammonia-free plasma deposition for III-nitride growth (originally 500–700°C versus >950°C for MOCVD). Historically pitched for LEDs, micro-LEDs, power electronics and tunnel-junction laser diodes (first RPCVD tunnel-junction laser diodes demonstrated c.2022). Currently a secondary/optional commercialisation path.
Financial Narrative
All A$M, fiscal years ending 30 June. Sources: Appendix 4E/Annual Reports FY2022–FY2026; FY2022–FY2024 revenue and operating cash flow lines from Stoxray/TipRanks aggregations of reported figures; FY2023–FY2024 cash and D&A from InvestSMART/Morningstar.
Income statement
Notes: Gross profit is not disclosed (expenses by nature; no COGS). EBITDA derived as net loss + D&A + finance cost − finance income (no tax expense). FY2022 net loss of A$9.36M is consistent with the FY2023 4E statement that the loss rose 25.6% to A$11.75M. FY2023 total income ~A$9.5M per Stonegate. The FY2025 per-share figure was restated from −0.59c to −11.74c after consolidation (the ×20 conversion of −0.59c gives −11.8c; the small difference reflects the restated weighted-average share count of 93.5M).
Margins and growth
Revenue CAGR (FY2022–FY2026, customer revenue): ~61% per annum (A$0.60M to A$4.06M). This flatters the trajectory: FY2024 included a one-off A$1.93M IP transfer, and FY2026 revenue fell 25%.
Balance sheet
Notes: Borrowings are Radium Capital (Innovation Structured Finance Co., LLC) loans secured against the R&D tax rebate, 16.5% interest, maturing 31 October 2026; A$2.41M (principal, interest, fees) was repaid 1 July 2026. Intangibles: A$12.13M in-process R&D fully impaired. There is no long-term financial debt.
Ratios (derived)
n/m = not meaningful (negative EBITDA/EBIT). Cash conversion cycle cannot be computed without COGS.
Commentary on trends, inflections and drivers
Persistent ~A$10–12M annual losses. Net losses have ranged between A$9.4M and A$11.8M for five years, with no structural inflection. FY2026's 5% improvement came mostly from a A$0.29M share-based payment credit (reversal of A$0.54M of expense on lapsed director performance rights), lower depreciation (A$2.83M vs A$3.29M) and lower consumables (A$2.70M vs A$3.17M) — not from revenue growth. Employee costs fell 6% to A$7.98M; board and secretarial fees rose 21% to A$0.66M and travel rose 76% to A$0.45M, reflecting the US-centred board and government-relations push.
Revenue quality. Customer revenue peaked at A$5.45M in FY2025. FY2026's decline reflects the foundry exit (−A$0.68M) and US government delays on projects (−A$0.84M). Product revenue (A$0.50M) remains immaterial relative to the cost base. Gross expenditure was A$20.87M in FY2026, roughly 5x customer revenue.
R&D Tax Incentive dependence. The refundable offset contributed A$6.05M (FY2025) and A$6.12M (FY2026), more than customer revenue in both years. Because the offset is a percentage of eligible spend, it partly scales with losses — it is a subsidy, not a commercial validation. The company pre-finances it through Radium Capital at 16.5%, which raised finance costs to A$0.59M.
Cash burn and funding. Operating cash outflow worsened 35% to A$8.30M in FY2026 as customer receipts fell 39%. Cash nearly doubled to A$11.34M only because of A$14.6M of equity raised. At the Q3 FY2026 quarter-end (31 March 2026), cash was just A$2.72M (Appendix 4C), illustrating how close the company came to a funding crunch before the April–June raise. Auditors' going-concern basis carries a material uncertainty in FY2026 (and the FY2025 commentary on Quartr also referenced going-concern risk).
Dilution. Shares on issue rose 57% in FY2026 (120.7M to 190.0M post-consolidation), and pre-consolidation shares had already expanded from ~1.8bn to 2.4bn in FY2025 via raises at A$0.013. A further 55.0M options (mostly A$0.38 strike, expiring May 2028) are outstanding — potentially ~A$20.9M of future funding if exercised, but at the cost of ~29% further dilution.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Country | Ownership 30 Jun 2026 | Role |
|---|---|---|---|
BluGlass Limited | Australia | Parent | Listed holding/operating company; Silverwater epitaxy and R&D |
BluGlass Incorporated | United States | 100% | US operations, Fremont fab, US government/defence contracting entity (e.g., India MoD supplier approval was in the name of BluGlass Inc) |
Gallium Enterprises Pty Ltd | Australia | 100% | Not described in sources accessed |
EpiBlu Technologies Pty Ltd | Australia | 100% | Former JV vehicle (2010) |
Semiconductor Industry Australia Pty Ltd | Australia | 100% (reduced to 19.9% on 7 Jul 2026) | Semiconductor Australia conference vehicle |
Revenue by Segment
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Laser Diode Project Revenue (AUD Mn) | — | 3.39 | 2.55 |
Laser Diode Product Revenue (AUD Mn) | — | 0.37 | 0.50 |
Foundry Services Revenue (AUD Mn) | — | 1.69 | 1.01 |
Total Revenue from Customers (AUD Mn) | 4.62 | 5.45 | 4.06 |
R&D Tax Incentive Income (AUD Mn) | — | 6.05 | 6.12 |
Other Income incl. finance income (AUD Mn) | — | 0.20 | 0.30 |
Total Revenue + Other Income (AUD Mn) | 10.10 | 11.70 | 10.48 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2025 | FY2026 |
|---|---|---|
Project Revenue YoY growth (%) | — | -24.7 |
Product Revenue YoY growth (%) | — | 35.5 |
Foundry Revenue YoY growth (%) | — | -40.3 |
Project share of customer revenue (%) | 62.2 | 62.9 |
Product share of customer revenue (%) | 6.7 | 12.3 |
Foundry share of customer revenue (%) | 31.0 | 24.9 |
R&D Tax Incentive share of total income (%) | 51.7 | 58.4 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from customers (AUD Mn) | 0.60 | 1.15 | 4.62 | 5.45 | 4.06 |
Total revenue and other income (AUD Mn) | — | 9.50 | 10.10 | 11.70 | 10.48 |
Depreciation and amortisation (AUD Mn) | — | 3.90 | 3.00 | 3.29 | 2.83 |
Finance cost (AUD Mn) | — | — | — | 0.44 | 0.59 |
EBITDA, derived (AUD Mn) | — | — | — | -7.30 | -6.98 |
Pre-tax income (AUD Mn) | -9.36 | -11.75 | -10.14 | -10.98 | -10.39 |
Net income (AUD Mn) | -9.36 | -11.75 | -10.14 | -10.98 | -10.39 |
EPS basic, as reported (A$ cents) | -0.89 | -0.86 | -0.63 | -0.59 | -7.51 |
EPS basic, consolidation-adjusted (A$ cents) | -17.80 | -17.20 | -12.60 | -11.74 | -7.51 |
EPS diluted (A$ cents, adjusted) | -17.80 | -17.20 | -12.60 | -11.74 | -7.51 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 66.3 | 89.5 | 302.9 | 18.0 | -25.5 |
Net margin on customer revenue (%) | -1,547 | -1,025 | -220 | -201 | -256 |
Net margin on total income (%) | — | -124 | -100 | -94 | -99 |
EBITDA margin on customer revenue, derived (%) | — | — | — | -134 | -172 |
Operating margin, InvestSMART definition (%) | — | -662.6 | -93.9 | -133.9 | — |
Balance Sheet and Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Total assets (AUD Mn) | — | — | 23.93 | 27.41 |
Cash and equivalents (AUD Mn) | 4.26 | 5.57 | 5.74 | 11.34 |
Trade and other receivables incl. R&D rebate (AUD Mn) | — | — | 7.77 | 7.70 |
Short-term borrowings (AUD Mn) | — | — | 3.05 | 4.54 |
Lease liabilities current (AUD Mn) | — | — | 0.78 | 0.87 |
Lease liabilities non-current (AUD Mn) | — | — | 3.27 | 2.65 |
Total debt incl. leases (AUD Mn) | — | — | 7.10 | 8.06 |
Net debt / (net cash) (AUD Mn) | — | — | 1.37 | -3.28 |
Total equity (AUD Mn) | — | 14.89 | 11.59 | 14.41 |
Goodwill and intangibles (AUD Mn) | — | — | 0 | 0 |
Working capital (AUD Mn) | — | — | 7.13 | 11.75 |
Accumulated losses (AUD Mn) | — | 98.06 | 109.03 | 119.42 |
Issued capital (AUD Mn) | — | 112.58 | 120.08 | 134.57 |
NTA per share (A$ cents, post-consolidation) | — | — | 15.17 | 16.76 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD Mn) | — | — | — | 6.91 | 4.23 |
R&D tax rebate received (AUD Mn) | — | — | — | 5.37 | 6.07 |
Operating cash flow (AUD Mn) | -6.26 | -11.88 | -6.95 | -6.15 | -8.30 |
Capex — plant and equipment (AUD Mn) | — | — | — | 1.81 | 1.21 |
Free cash flow, derived (AUD Mn) | — | — | — | -7.96 | -9.51 |
Equity raised, net (AUD Mn) | — | — | — | 7.45 | 14.61 |
Net borrowings (AUD Mn) | — | — | — | 1.90 | 1.49 |
Lease principal repaid (AUD Mn) | — | — | — | 0.78 | 1.01 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%)
| Ratio | FY2025 | FY2026 |
|---|---|---|
ROE (%; net loss / average equity) | -82.9 | -79.9 |
ROA (%; net loss / year-end assets) | -45.9 | -37.9 |
ROIC (%)
| ROIC (%) | n/m | n/m |
|---|---|---|
Current ratio (x) | 1.95 | 2.34 |
Debt / equity incl. leases (x) | 0.61 | 0.56 |
Net debt / EBITDA (x)
| Net debt / EBITDA (x) | n/m | n/m |
|---|---|---|
Interest coverage (x) | n/m | n/m |
Asset turnover (x; customer revenue / year-end assets) | 0.23 | 0.15 |
Revenue by Region and Revenue by Region (%)
| Indicator | FY2025 | FY2026 |
|---|---|---|
Accumulated tax losses — Australia (AUD Mn) | 25.83 | 26.59 |
Accumulated tax losses — United States (AUD Mn) | 6.06 | 10.76 |
US share of pipeline opportunities by value (%) | — | 80 |
US Government share of pipeline opportunities (%) | — | 60 |
Valuation Snapshot
| Metric | Value |
|---|---|
52-week range | A$0.175 – A$0.55 |
Calendar 2026 YTD (to Aug 2026) | approx. +40% to +57% (from A$0.235 starting price) |
FY2026 return (unadjusted data shows +3,567%, distorted by consolidation) | Approx. +83% on consolidation-adjusted basis (A$0.18 to A$0.33; derived from A$0.009 × 20) |
1-year (to Aug 2026) | approx. +62.5% (Investing.com) |
FY2025 shareholder return | -72.8% (InvestSMART) |
FY2024 shareholder return | -19.4% (InvestSMART) |
FY2023 shareholder return | 57.8% (InvestSMART) |
3-year return | Strongly negative (cumulative FY2024–FY2026 approx. -73% derived from annual figures above; indicative only) |
Metric | FY2023 |
Annual shareholder return (%) | 57.8 |
Valuation Snapshot by Multiple
| Multiple | Value | Basis |
|---|---|---|
Market capitalisation | ~A$63M | Price × shares |
Enterprise value | ~A$60M | Market cap + A$8.06M debt incl. leases − A$11.34M cash (30 Jun 2026) |
EV / Sales (customer revenue FY2026) | ~14.7x | A$4.06M |
EV / total income (FY2026) | ~5.7x | A$10.48M |
P/B | ~4.4x | Equity A$14.41M |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
Obligation Details
| Obligation | Amount (AUD Mn) | Maturity / terms |
|---|---|---|
Radium Capital R&D-secured loans | 4.54 | 31 Oct 2026; 16.5% p.a.; A$2.41M repaid 1 Jul 2026; facility redrawable |
Lease payments within 1 year (undiscounted) | 1.32 | FY2027 |
Lease payments 1–5 years (undiscounted) | 2.89 | FY2028–FY2031 |
Lease payments >5 years (undiscounted) | 0.22 | To Feb 2033 (Silverwater) |
Debt maturity bucket (AUD Mn) | FY2027 | FY2028-FY2031 |
Borrowings and leases (undiscounted) | 5.86 | 2.89 |
Share Price & Returns
| Date | Instrument | Price (post-consolidation equivalent) | Gross proceeds (AUD Mn) |
|---|---|---|---|
FY2024 | Placement + SPP | — | 10.17 |
May–Jul 2025 | Placement + SPP + shortfall | A$0.26 (A$0.013 pre-consolidation) | 7.63 |
Sep 2025–May 2026 | A$0.26 option exercises | A$0.26 | 5.06 |
Apr–Jun 2026 | Two-tranche placement | A$0.24 | 8.05 |
Jun 2026 | Option shortfall (Amery Partners) | A$0.26 | 1.50 |
Analyst Conclusions
Management guidance
No quantitative financial guidance. Management targets conversion of the US$100M pipeline into revenue-generating contracts, new and repeat orders, technology roadmap progress (higher power, longer wavelengths), expanded US Government engagement and access to non-dilutive grants, and investment in new equipment and personnel. Strongest demand is cited in defence and aerospace, quantum, biotech and consumer electronics.
Consensus expectations
Not available (no consensus coverage).
Bull case
-
Design-in conversion: Three concurrent programs with large counterparties (Tier-1 prime A$1.25M, Fortune 500 A$1.3M, Uviquity Phase II A$1.4M) plus the Coherent collaboration create multiple shots at production supply agreements within 12–24 months; a single volume supply agreement could multiply product revenue from A$0.5M.
-
Strategic scarcity value: As one of two US-located GaN laser manufacturers with Department of War-approved supplier status, BluGlass's fab and IP could command a strategic premium; at ~A$60M EV, the company trades near the replacement cost management cited for the fab alone (~US$40M) plus IP.
-
Funded runway and aligned board: A$11.3M cash, net cash position, ~A$6M annual R&D rebate, and A$20.9M of in-the-money-contingent A$0.38 options provide 12–18 months of runway; the board has invested personally (A$2.27M) and has capital-markets networks to pursue non-dilutive US funding and M&A.
Bear case
-
Structural cash burn without commercial inflection: Five consecutive years of ~A$10–12M losses, customer revenue down 25% in FY2026, and Q4 FY2026 customer receipts of only A$0.20M demonstrate that the project model has not yet scaled; historic targets (6–10% market share and positive cash flow by 2024/25) were missed by wide margins.
-
Dilution treadmill: Share count up 57% in FY2026 alone, plus 55M options outstanding; going-concern material uncertainty persists, and every year of operation at the current burn rate requires ~A$8–10M of new capital.
-
Governance and capital-allocation risk: A non-majority-independent board led by an executive chair, overlapping investor relationships among directors, and a US$1.5M loan to a start-up customer raise questions about capital discipline; a pivot to "inorganic" growth could add complexity and further dilution.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Oct 2026 | Q1 FY2027 Appendix 4C — customer receipts trend; repayment of Radium loans by 31 Oct 2026 |
| Oct 2026 onwards | Receipt of FY2026 R&D Tax Incentive refund (~A$6.13M receivable) |
| Nov 2026 | 2026 AGM — approval of piggyback options and CEO LTI; board composition votes; any "first strike" risk on remuneration |
| H1 FY2027 | CLAWS Hub Year-4 award (US federal FY2027 budget timing) |
| H1–H2 FY2027 | Tier-1 defence prime program phase-2 order; Fortune 500 milestone payments |
| FY2027 | Uviquity Master Supply Agreement negotiation; repayment of US$1.5M promissory note (Jul 2027) |
| FY2027 | Non-dilutive US Government grant award (DoW/DoE) — evidence of Michael Best engagement payoff |
| FY2027 | Any announced M&A or strategic transaction |
| Feb 2027 | H1 FY2027 half-year report — revenue mix, cash burn |
| Ongoing | Exercise of A$0.38 options (expire 31 May 2028) — share price must exceed A$0.38 |
Analyst verdict
BluGlass enters FY2027 in a better position than at any time in the past three years — but that bar is low. The company has executed a credible operational and governance reset: a US-centred board, a recapitalisation that lifted cash to A$11.3M and eliminated net debt, and a second half of FY2026 that produced five new development contracts worth just under A$5.2M with counterparties of genuine quality (a US Tier-1 defence prime, a Fortune 500 company, TOPTICA, Uviquity, and, subsequently, Coherent). Its US fab and Department of War credentials are scarce assets in a world prioritising sovereign photonics supply, and its single-mode and DFB results show real technical capability.
The financial reality, however, has not changed. Customer revenue of A$4.1M fell 25% in FY2026, product sales remain below A$0.5M, the R&D Tax Incentive is the largest income line, operating cash burn rose to A$8.3M, and the auditors' going-concern basis carries a material uncertainty. The project-to-product model has been the stated strategy since at least 2023, and management's own earlier aspirations — significant market share and positive cash flow by 2024–26 — have not materialised. Pipeline figures (US$100M; earlier >A$154M) should be treated as indicative rather than predictive, given conversion rates to date.
At ~A$60M enterprise value, the market is pricing BluGlass as a strategic option rather than an operating business. That option has value: a single production supply agreement, a meaningful non-dilutive US award, or a strategic transaction could re-rate the stock. Absent those, the base case is continued annual capital raising and dilution. Our assessment is that BluGlass is a high-risk, binary, event-driven speculation. The key evidence to watch over the next 12 months is not new development contracts, but the first multi-year product supply agreement and a sustained rise in quarterly customer receipts above ~A$2M.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Independence | Background | Education |
|---|---|---|---|---|---|
Omer Granit | Executive Chair | Director 15 Sep 2025; Exec Chair 10 Nov 2025 | Not independent (executive; engaged as independent contractor) | Partner, EnPar Capital (New York); co-founder/managing member, June 76 (NY/Tel Aviv investment firm); founded MIXER (co-working) and West 4 Capital (UK hedge fund); ex-White & Case M&A attorney; NED of Amaero (ASX: 3DA) since Jan 2023 | LLM (NYU, valedictorian); LLB and BA, Reichman University; admitted in New York and Israel |
James (Jim) Haden | CEO & Managing Director | President Sep 2021; CEO Mar 2023; Director 9 Dec 2025; MD 13 Jul 2026 | Not independent | 30+ years laser diode industry; senior roles at Kyocera SLD, nLIGHT, Coherent, JDS Uniphase (now Lumentum) | MS and BS, University of Southern California (Quantum and Solid-State Physics) |
Lucy Robb Vujcic | Independent NED; Audit & Risk Committee Chair; Remuneration Committee member | 10 Nov 2025 | Independent | Commercial barrister; corporate law, defence procurement, government contracting, international arbitration; ex-Skadden Arps associate; former NED Amaero (Oct 2022–Oct 2024) | BA/LLB (First Class Hons), University of Sydney; LLM, NYU; FGIA |
Ata Gokyildirim | Independent NED; Remuneration Committee Chair; Audit & Risk Committee member | 10 Nov 2025 | Independent (per company) | Chief Revenue Officer, Insait IO; former Chair, Prima BioMed (now Immutep); roles at Forter, Sedric, LoudNClear | B Comm |
Yam Rubenstein | NED | 21 Aug 2026 | Not stated; analyst view: not independent given co-control of J76 BLG LLC with Executive Chair | Founder/CEO 102 Percent Ltd; 10+ years Deputy CEO, Migdal Capital Markets; advisory board, Cyabra (Nasdaq); co-founder June 76 | Bachelor of Commerce |
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
Jim Haden | CEO & Managing Director | See above |
Samuel Samhan | Chief Financial Officer | Investor/media contact on 2026 announcements |
Ian Mann | Chief Operations & Technology Officer | Long-tenured technical executive |
Brad Siskavich | Vice President | US-based (inferred from remuneration currency effects; not confirmed) |
Stefanie Winwood | Investor relations/communications contact (2025 announcements) | Not KMP |
Andrew Palfreyman | Company Secretary (contracted) | From 6 Jan 2026; predecessor Patricia Vanni (Jul 2024–Jan 2026) |
Directors' Remuneration
| Executive | Cash salary | Cash STI | STI share-based | Superannuation | LTI share-based | Total | % share-based |
|---|---|---|---|---|---|---|---|
Omer Granit (Exec Chair) | 296,688 | 0 | 0 | 0 | 0 | 296,688 | 0 |
Jim Haden (CEO) | 411,485 | 0 | 73,913 | 31,966 | 30,107 | 547,471 | 19.0 |
Samuel Samhan (CFO) | 291,200 | 0 | 55,401 | 39,989 | 25,445 | 412,035 | 19.6 |
Ian Mann (COO/CTO) | 294,899 | 0 | 53,082 | 40,285 | 24,916 | 413,182 | 18.9 |
Brad Siskavich (VP) | 311,418 | 0 | 50,722 | 62,856 | 24,743 | 449,739 | 16.8 |
Total executives | 1,605,690 | 0 | 233,118 | 175,096 | 105,211 | 2,119,115 | — |
Executive total remuneration (AUD) | FY2025 | FY2026 | — | — | — | — | — |
Jim Haden | 620,826 | 547,471 | — | — | — | — | — |
Samuel Samhan | 394,316 | 412,035 | — | — | — | — | — |
Ian Mann | 396,384 | 413,182 | — | — | — | — | — |
Brad Siskavich | 466,338 | 449,739 | — | — | — | — | — |
All executives | 1,877,863 | 2,119,115 | — | — | — | — | — |
Major Shareholders
| Holder | Shares | Approx. % of 190.0M |
|---|---|---|
J76 BLG LLC (Granit and Rubenstein relevant interest) | 8,333,334 | 4.4 |
Jim Haden (direct + ESS trust) | 1,389,038 | 0.7 |
Ian Mann | 755,399 | 0.4 |
Ata Gokyildirim | 625,000 | 0.3 |
Brad Siskavich | 470,695 | 0.2 |
Samuel Samhan | 345,000 | 0.2 |
Total disclosed board/KMP | 11,918,466 | 6.3 |
Competitive Landscape
Key Competitors
| Competitor | Country | Relevance to BluGlass | Positioning vs BluGlass |
|---|---|---|---|
Nichia Corporation | Japan | Dominant global GaN laser diode supplier (blue/violet; projectors, industrial) | Massive scale and cost leadership; private, segment data not disclosed |
Kyocera SLD Laser | USA (Kyocera subsidiary) | GaN laser light sources (laser lighting); US-based (California) — plausibly the other US GaN laser manufacturer management references | Larger, backed by Kyocera; CEO Haden is an alumnus |
ams OSRAM | Austria/Germany | Blue/green GaN laser diodes for projection, automotive, industrial | — |
Sharp (Fukuyama laser operations) | Japan | GaN violet/blue laser diodes | Established volume supplier |
Ushio | Japan | Visible laser diodes (red/green/blue) | Broad lamp/laser portfolio |
Coherent | USA | Lasers/photonics giant; now also a BluGlass collaborator | — |
nLIGHT | USA | US-based semiconductor laser manufacturer (primarily infrared) and defence laser systems | — |
NUBURU | USA | Blue industrial lasers (uses GaN diodes from third parties) | Potential customer/competitor at system level; financially distressed |
Exalos / other SLD makers | Switzerland | Visible superluminescent diodes | Niche competitor for some sensing applications |
Enkris Semiconductor | China | GaN epitaxy (CB Insights-listed competitor) | Competes in epitaxy/foundry rather than lasers |
Chinese GaN laser makers (e.g., multiple domestic suppliers) | China | Low-cost blue laser diodes | Excluded from many US defence programs by sourcing rules — a BluGlass advantage |
Peer Comparison FY2026
| Metric | BluGlass FY2026 | Coherent FY2025 | nLIGHT FY2024 | ams OSRAM FY2024 |
|---|---|---|---|---|
Revenue (local currency, M) | 4.06 (A$) | 5810 (US$) | 199 (US$) | 3430 (EUR) |
Revenue growth (%) | -25.5 | — | — | — |
Net margin (%) | -256 | — | — | — |
Recent Developments
--



